ClinicalTrials.gg
Active, not recruitingNCT06495918Updated Jun 17, 2025

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

A Phase 3 interventional study of OTX-TKI and Aflibercept in Neovascular Age-related Macular Degeneration, sponsored by Ocular Therapeutix, Inc.. Active, not recruiting at 97 sites in 4 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.

Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
825
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Planned enrollment
27th of 491
825 · median 55
Started
2024
with 23 others
Phase 3
86 of 645
8 open now
Primary completion
2027-01
later than 42 of 124 live
Registered
575th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 27th largest by planned enrollment of the 491 interventional ones that give a count, is one of 24 that started in 2024, is one of 86 in phase 3, reaches primary completion later than 42 of the 124 other live ones, and was the 575th registered.

Macular Degeneration

1,460 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • Neovascular Age-Related Macular Degeneration
  • Tyrosine Kinase Inhibitor
  • OTX-TKI
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment naïve juxtafoveal and/or SFNV secondary to Neovascular Age- Related Macular Degeneration (nAMD) with leakage involving the fovea in the study eye prior to Screening, or have a diagnosis of Neovascular Age- Related Macular Degeneration (nAMD) in study eye within 3 months prior to screening and received up to 2 monthly injections of 2 mg aflibercept with last injection approximately 4 weeks prior to Screening
  • Have provided written consent

Exclusion criteria

Exclusion Criteria:

  • Monocular subject or Best Corrected Visual Acuity (BCVA) score of \<20 ETDRS letters or 20/400 in fellow eye at Screening
  • Have evidence of a scar, fibrosis, or atrophy of >50% of the total lesion in the study eye.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
825 participants (estimated)

Study arms

  • Experimental
    OTX-TKI Re-dose

    Drug: OTX-TKI

  • Active comparator
    Aflibercept 2mg on label

    Drug: Aflibercept

  • Other
    Aflibercept 8mg high dose

    Drug: Aflibercept

Interventions

  • Intravitreal Injection of OTX-TKI

  • Intravitreal Injection of 2mg of aflibercept

  • Intravitreal Injection of 8mg of aflibercept

06

What researchers measure

Primary outcomes

  1. Best Corrected Visual Acuity (BCVA)

    Mean change in Best Corrected Visual Acuity (BCVA) from baseline at Week 48

    Time frame: Week 48

07

Study locations

97 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 25 months after the start.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 25 months is close to that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2024
First posted
Jul 11, 2024
StartActual
Nov 27, 2024
Primary completionEst.
Jan 8, 2027
CompletionEst.
Jan 8, 2027
Last update
Jun 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06495918
Collaborators
Fortrea, Duke University
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Nov 27, 2024
Primary completion
Jan 8, 2027 (estimated)
Completion
Jan 8, 2027 (estimated)
Last update
Jun 17, 2025

Study contacts

Dilsher Dhoot, MD
principal investigator · California Retina Consultants (CRC) - Santa Barbara

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion